Multiplex diagnosis of oncogenic fusion and met exon skipping by molecular counting using formalin-fixed paraffin embedded lung adenocarcinoma tissues

Journal of Thoracic Oncology

Volumn 11, Issue 2, 2016, Pages 203-212

  Sunami, Kuniko ^a,c   Furuta, Koh ^b   Tsuta, Koji ^a   Sasada, Shinji ^a   Izumo, Takehiro ^a   Nakaoku, Takashi ^a   Shimada, Yoko ^a   Saito, Motonobu ^a   Nokihara, Hiroshi ^a   Watanabe, Shun Ichi ^b   Ohe, Yuichiro ^a,c   Kohno, Takashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Genetic diagnosis; MET exon skipping; Molecular counting; Oncogene fusion; Personalized medicine

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; NEU DIFFERENTIATION FACTOR; PROTEIN RET; SCATTER FACTOR RECEPTOR; FORMALDEHYDE; MESSENGER RNA; MET PROTEIN, HUMAN; PARAFFIN;

ACCURACY; ARTICLE; CANCER TISSUE; EXON SKIPPING; GENE EXPRESSION; GENE FUSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR COUNTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TRACHEOBRONCHIAL TOILET; TRANSBRONCHIAL BIOPSY; TRANSCRIPTOMICS; TUMOR BIOPSY; ADENOCARCINOMA; EXON; GENETICS; LUNG TUMOR;

ADENOCARCINOMA; EXONS; FORMALDEHYDE; GENE FUSION; HUMANS; LUNG NEOPLASMS; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS C-MET; RNA, MESSENGER;

EID: 84958951896     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.10.005     Document Type: Article

References (35)

1. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013;13:772-787.
2. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013;31:1097-1104.
3. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New Engl J Med. 2010;363:1693-1703.
4. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALKrearranged non-small-cell lung cancer. New Engl J Med. 2014;370:1189-1197.
5. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-Arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14: 590-598.
6. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.
7. Janne PA, Meyerson M. ROS1 rearrangements in lung cancer: A new genomic subset of lung adenocarcinoma. J Clin Oncol. 2012;30:878-879.
8. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18:375-377.
9. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382-384.
10. Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearranged lung cancer: A clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol. 2013;37:554-562.
11. Drilon AE, Sima CS, Somwar R, et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers [abstract]. Presented at: 51st Annual Meeting of the American Society of Clinical Oncology. May 29-June 2, 2015; Chicago, IL.
12. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. New Engl J Med. 2015;372:683-684.
13. Falchook GS, Ordonez NG, Bastida CC, et al. Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer [e-pub ahead of print]. J Clin Oncol. http://dx.doi.org/10.1200/JCO.2013.50.5016 accessed January 4, 2016.
14. Nakaoku T, Tsuta K, Ichikawa H, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014;20:3087-3093.
15. Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4:415-422.
16. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006;66:283-289.
17. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 2009;4:5-11.
18. Paik PK, Drilon A, Yu H, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5:842-849.
19. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850-859.
20. Mizukami T, Shiraishi K, Shimada Y, et al. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma. J Thorac Oncol. 2014;9:622-630.
21. Network CGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543-550.
22. Lira ME, Kim TM, Huang D, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn. 2013;15: 51-61.
23. Lira ME, Choi YL, Lim SM, et al. A single-Tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn. 2014;16:229-243.
24. Kinno T, Tsuta K, Shiraishi K, et al. Clinicopathological features of non-small cell lung carcinomas with BRAF mutations. Ann Oncol. 2014;25:138-142.
25. Saito M, Shimada Y, Shiraishi K, et al. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. Cancer Res. 2015;75:2264-2271.
26. Travis W, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2004.
27. Li A, Liu Z, Lezon-Geyda K, et al. GPHMM: An integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucl Acids Res. 2011;39:4928-4941.
28. Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4:156-164.
29. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22:2109-2119.
30. Tsuta K, Kozu Y, Mimae T, et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol. 2012;7:331-339.
31. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19:1469-1472.
32. Shan L, Jiang P, Xu F, et al. BIRC6-ALK, a novel fusion gene in ALK break-Apart FISH-negative lung adenocarcinoma, responds to crizotinib. J Thorac Oncol. 2015;10:e37-e39.
33. Jang JS, Lee A, Li J, et al. Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers. Sci Rep. 2015;5: 9755.
34. Ou SH, Chalmers ZR, Azada MC, et al. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. Lung Cancer. 2015;88:352-354.
35. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31:2783-2790.